Alkem Laboratories Share Price | Alkem Laboratories Stock Screener
ALKEM
Pharmaceuticals
Share Price NSE
₹5451.50
▲
71.50 (1.33%)
Share Price BSE
₹5452.25
▲
73.25 (1.36%)
As of May 27, 2026, the Alkem Laboratories share price (NSE: ALKEM) is ₹5,451.50 on NSE and ₹5,452.25 on BSE, up 1.33% from the previous close, with shares trading between ₹5,329.00 and ₹5,521.50, and a 52-week range of ₹4,732.80–₹5,890.00.
Check ALKEM 52-week chart for the annual price range and momentum.
Use the Alkem Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Alkem Laboratories Market Cap
₹64,134.67 Cr.
ALKEM P/E Ratio (TTM)
26.68
Alkem Laboratories P/B Ratio
4.84
EPS (TTM)
₹181.11
Dividend Yield
0.83%
Debt to Equity
0.13
ALKEM 52 Week High
₹5890.00
Alkem Laboratories 52 Week Low
₹4732.80
Operating Margin
12.00%
Profit Margin
9.79%
ALKEM Revenue (TTM)
₹3,290.00
EBITDA
₹537.00
Net Income
₹322.00
Total Assets
₹17,691.00
Total Equity
₹12,434.00
Alkem Laboratories Share Price Chart
Screen Alkem Laboratories share price with an interactive chart. Analyse ALKEM price trends and volatility across different timeframes.
Alkem Laboratories Company Profile - Fundamental Screener
Screen Alkem Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ALKEM shares.
Alkem Laboratories Limited is an Indian pharmaceutical company headquartered in Mumbai, with global operations. The company develops, manufactures, and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. It has a portfolio of over 800 brands in India and operates in more than...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Basudeo N Singh
ISIN
INE540L01014
Website
https://www.alkemlabs.com
Alkem Laboratories Balance Sheet Screener
Screen ALKEM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 17,691 | 15,575 | 13,757 | 14,069 | 11,519 | 9,946 | 8,208 | 7,666 | 6,568 | 5,535 |
| Current Assets | 10,811 | 10,412 | 8,730 | 8,434 | 6,929 | 5,506 | 4,216 | 4,013 | 2,917 | 2,769 |
| Fixed Assets | 2,852 | 2,873 | 2,683 | 2,902 | 2,793 | 2,908 | 2,530 | 2,284 | 1,797 | 1,450 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,299 | 866 | 615 | 417 | 357 | 392 | 446 | 297 | 296 | 210 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 12,434 | 10,714 | 9,435 | 8,847 | 7,558 | 6,309 | 5,572 | 4,985 | 4,583 | 3,787 |
| Share Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves & Surplus | 11,961 | 10,288 | 9,021 | 8,614 | 7,353 | 6,137 | 5,415 | 4,840 | 4,444 | 3,668 |
Alkem Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Alkem Laboratories income statement and profit fundamentals.
Analyze ALKEM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Alkem Laboratories share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,290 | 3,521 | 4,105 | 3,880 | 3,024 | 3,152 | 3,549 | 3,467 | 2,971 | 3,034 | 3,503 | 3,418 | 2,504 | 2,628 | 3,130 |
| Expenses | 2,753 | 2,632 | 3,080 | 2,962 | 2,546 | 2,423 | 2,662 | 2,615 | 2,652 | 2,579 | 2,751 | 2,668 | 2,162 | 2,373 | 2,626 |
| EBITDA | 537 | 889 | 1,025 | 918 | 478 | 729 | 887 | 852 | 319 | 455 | 752 | 750 | 343 | 255 | 505 |
| Operating Profit % | 12.00% | 22.00% | 23.00% | 21.00% | 13.00% | 20.00% | 22.00% | 23.00% | 9.00% | 13.00% | 20.00% | 20.00% | 13.00% | 8.00% | 15.00% |
| Depreciation | 113 | 88 | 94 | 95 | 83 | 81 | 79 | 85 | 78 | 72 | 74 | 70 | 83 | 76 | 77 |
| Interest | 28 | 30 | 35 | 42 | 27 | 29 | 28 | 36 | 29 | 30 | 30 | 26 | 17 | 27 | 25 |
| Profit Before Tax | 396 | 771 | 896 | 781 | 367 | 619 | 780 | 731 | 212 | 353 | 648 | 655 | 243 | 152 | 402 |
| Tax | 74 | 103 | 117 | 128 | 63 | 69 | 78 | 90 | 144 | 65 | 33 | 51 | 135 | 20 | 55 |
| Net Profit | 322 | 668 | 779 | 653 | 305 | 550 | 702 | 641 | 68 | 288 | 615 | 604 | 108 | 131 | 348 |
| EPS | 25.57 | 55.56 | 63.99 | 53.19 | 24.55 | 45.60 | 57.60 | 52.34 | 5.94 | 23.98 | 51.90 | 49.76 | 9.00 | 10.68 | 27.67 |
Alkem Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen ALKEM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,913 | 1,948 | 1,683 | 1,111 | 1,265 | 585 | 780 | 266 | 471 | 726 |
| Investing Activities | -1,288 | -1,011 | 120 | -1,433 | -995 | -737 | -318 | -351 | -294 | 205 |
| Financing Activities | -811 | -1,145 | -1,761 | 380 | -272 | 79 | -379 | 85 | -138 | -927 |
| Net Cash Flow | -186 | -208 | 42 | 58 | -2 | -73 | 82 | 0 | 40 | 3 |
Alkem Laboratories Shareholding Pattern Screener
See Alkem Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Alkem Laboratories promoter holding and ownership changes for ALKEM on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.20% | 55.13% | 53.04% | 51.20% | 51.20% | 56.74% | 56.38% | 55.66% |
| FII Holding | 10.16% | 9.41% | 9.11% | 9.48% | 9.97% | 9.11% | 8.69% | 9.02% |
| DII Holding | 21.40% | 19.42% | 21.80% | 21.93% | 21.54% | 15.63% | 18.57% | 19.21% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 17.06% | 15.77% | 15.69% | 17.18% | 17.09% | 18.31% | 16.15% | 15.84% |
| Other Holding | 0.19% | 0.28% | 0.36% | 0.22% | 0.21% | 0.21% | 0.21% | 0.26% |
| Shareholder Count | 62,835 | 84,326 | 79,740 | 67,196 | 64,536 | 65,830 | 69,627 | 74,744 |
Alkem Laboratories Share Dividend Screener - Share Yield Analysis
Check Alkem Laboratories dividend history with payout and yield data.
View Alkem Laboratories dividend details including ex-dates and amounts for ALKEM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹45.00 | 0.85% |
| 2024-March | ₹40.00 | 0.82% |
| 2023-March | ₹50.00 | 1.01% |
| 2022-March | ₹34.00 | 1.03% |
| 2021-March | ₹30.00 | 0.83% |
| 2020-March | ₹25.00 | 0.90% |
| 2019-March | ₹16.00 | 0.69% |
| 2018-March | ₹13.00 | 0.74% |
| 2017-March | ₹15.00 | 0.75% |
Alkem Laboratories Stock Index Membership
See which indices include Alkem Laboratories stock.
Check ALKEM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 200
NIFTY 500
NIFTY ALPHA QUALITY VALUE LOW VOLATILITY 30
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY LOW VOLATILITY 50
NIFTY MIDCAP 100
NIFTY MIDCAP 150
NIFTY MIDCAP 50
NIFTY MIDSMALL INDIA CONSUMPTION
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
Alkem Laboratories Market Events Screener - Corporate Actions
Get Alkem Laboratories corporate actions including splits, bonuses, and buybacks.
Check Alkem Laboratories stock events that may affect ALKEM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-28 | 2026-05-28 | Quarterly Result Announcement | NA | -1.30% |
| 2026-02-20 | 2026-02-20 | Dividend | ₹ 43.00 /share | -8.45% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 1.82% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 3.97% |
| 2025-08-25 | 2025-08-25 | Annual General Meeting | NA | 3.05% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -1.11% |
| 2025-08-08 | 2025-08-08 | Dividend | ₹ 8.00 /share | -7.48% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | -0.22% |
| 2025-02-14 | 2025-02-14 | Dividend | ₹ 37.00 /share | -10.22% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 5.92% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -5.09% |
| 2024-08-30 | 2024-08-30 | Annual General Meeting | NA | 12.88% |
| 2024-08-09 | 2024-08-10 | Dividend | ₹ 5.00 /share | 9.08% |
| 2024-02-16 | 2024-02-17 | Dividend | ₹ 35.00 /share | 2.51% |
| 2023-08-10 | 2023-08-10 | Dividend | ₹ 10.00 /share | 27.09% |
Alkem Laboratories Competitors Screener - Peer Comparison
Screen ALKEM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 438,622 | 40.42 | 58,220 | 6.38% | 11,565 | 54.03 |
| Divis Laboratories | 178,607 | 73.73 | 10,560 | 8.73% | 2,520 | 57.30 |
| Torrent Pharmaceuticals | 151,410 | 66.80 | 13,753 | 19.18% | 2,028 | 66.36 |
| Cipla | 114,503 | 29.26 | 27,712 | -2.46% | 3,783 | 64.19 |
| Dr Reddys Laboratories | 111,759 | 26.24 | 33,593 | -0.44% | 3,998 | 57.44 |
| Zydus Life Science | 108,643 | 20.40 | 26,720 | 13.65% | 5,242 | 73.90 |
| Lupin | 103,749 | 19.46 | 27,488 | 19.98% | 5,345 | 48.15 |
| Mankind Pharma | 100,679 | 52.84 | 14,278 | 12.03% | 1,750 | 59.66 |
| Aurobindo Pharma | 84,751 | 24.29 | 33,385 | 3.21% | 3,376 | 51.11 |
| Laurus Labs | 73,636 | 81.46 | 6,813 | 21.03% | 884 | 78.36 |
Alkem Laboratories Company Announcements - News Screener
Screen ALKEM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-23 | Board Meeting Intimation for Board Meeting Intimation For Notice Of Meeting Of Board Of Directors Of The Company Scheduled To Be Held On 28Th May 2026. | - |
| 2026-05-22 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-08 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-05 | Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-05-02 | US FDA Inspection At CompanyS Manufacturing Facility Located At Amaliya Daman | - |
| 2026-04-24 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations) | - |
| 2026-04-24 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-04-13 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Incorporation Of Wholly Owned Subsidiary Of The Company | - |
| 2026-04-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-02 | Please Find Attached Herewith Intimation About Increase In Investment To Be Made For Setting Up Of Manufacturing Facility Of The Company In Ujjain Madhya Pradesh. | - |
| 2026-03-31 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-30 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Incorporation Of Wholly Owned Subsidiary Of The Company As A Scientific Office. | - |
| 2026-03-27 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-03-21 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-20 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-18 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 As Amended | - |